866 views2 min read
Silo Pharma Expands License Agreement and Patent Portfolio
Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June 23, 2022 -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a t... Read More...